tiprankstipranks
Surgery Partners Inc. (SGRY)
NASDAQ:SGRY
US Market
SGRY
Surgery Partners
RESEARCH TOOLSreports
Want to see SGRY full AI Analyst Report?

Surgery Partners (SGRY) Stock Forecast & Price Target

375 Followers
See the Price Targets and Ratings of:

SGRY Analyst Ratings

Strong Buy
8Ratings
Strong Buy
6 Buy
2 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Surgery
Partners
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SGRY Stock 12 Month Forecast

Average Price Target

$18.64
▲(18.52% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Surgery Partners in the last 3 months. The average price target is $18.64 with a high forecast of $24.00 and a low forecast of $14.00. The average price target represents a 18.52% change from the last price of $15.73.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","18":"$18","25":"$25","14.5":"$14.5","21.5":"$21.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.642857142857142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,14.5,18,21.5,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.4,16.06153846153846,16.723076923076924,17.384615384615387,18.046153846153846,18.70769230769231,19.369230769230768,20.03076923076923,20.692307692307693,21.353846153846156,22.015384615384615,22.676923076923078,23.338461538461537,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.4,15.649450549450549,15.8989010989011,16.14835164835165,16.397802197802196,16.647252747252747,16.896703296703297,17.146153846153847,17.395604395604394,17.645054945054945,17.894505494505495,18.143956043956045,18.393406593406592,{"y":18.642857142857142,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.4,15.292307692307693,15.184615384615386,15.076923076923077,14.96923076923077,14.861538461538462,14.753846153846155,14.646153846153846,14.538461538461538,14.430769230769231,14.323076923076924,14.215384615384615,14.107692307692307,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.185,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.88,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.26,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.27,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$24.00Average Price Target$18.64Lowest Price Target$14.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Benchmark Co. Analyst forecast on SGRY
Bill Sutherland
Benchmark Co.
Benchmark Co.
$24
Buy
52.57%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (NASDAQ: RLMD), Surgery Partners (NASDAQ: SGRY) and Apogee Therapeutics (NASDAQ: APGE)
KeyBanc Analyst forecast on SGRY
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Hold
―
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Surgery Partners (NASDAQ: SGRY), Axsome Therapeutics (NASDAQ: AXSM) and Pennant Group (NASDAQ: PNTG)
TD Cowen Analyst forecast on SGRY
Gary Taylor
TD Cowen
TD Cowen
$17→$19
Buy
20.79%
Upside
Assigned
08/11/26
TD Cowen Sticks to Their Buy Rating for Surgery Partners (SGRY)
RBC Capital Analyst forecast on SGRY
Ben Hendrix
RBC Capital
RBC Capital
$20→$19
Buy
20.79%
Upside
Reiterated
08/10/26
Analysts Are Bullish on Top Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Surgery Partners (SGRY)
Cantor Fitzgerald Analyst forecast on SGRY
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$18
Buy
14.43%
Upside
Reiterated
08/10/26
Surgery Partners' improved cash conversion not priced in, says Cantor FitzgeraldSurgery Partners' improved cash conversion not priced in, says Cantor Fitzgerald
Mizuho Securities Analyst forecast on SGRY
Ann Hynes
Mizuho Securities
Mizuho Securities
$19
Buy
20.79%
Upside
Reiterated
07/13/26
Mizuho Securities Sticks to Their Buy Rating for Surgery Partners (SGRY)
Bank of America Securities Analyst forecast on SGRY
Joanna Gajuk
Bank of America Securities
Bank of America Securities
$17.5
Buy
11.25%
Upside
Reiterated
05/14/26
Bank of America Securities Remains a Buy on Surgery Partners (SGRY)
Barclays Analyst forecast on SGRY
Andrew Mok CFA
Barclays
Barclays
$14
Hold
-11.00%
Downside
Assigned
05/12/26
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), Sarepta Therapeutics (NASDAQ: SRPT) and Surgery Partners (NASDAQ: SGRY)
Jefferies Analyst forecast on SGRY
Brian Tanquilut
Jefferies
Jefferies
$15→$17
Buy
8.07%
Upside
Reiterated
05/06/26
Raising PT to $17. With operations stabilizing, we believe we can now give SGRY credit for +HSD% LT EBITDA growth. Applying our coverage universe's avg valuation at 1.1x EBITDA growth rate to SGRY's earnings outlook translates to a 10x target multiple/our revised $17PT.
J.P. Morgan Analyst forecast on SGRY
Benjamin Rossi
J.P. Morgan
J.P. Morgan
$14
Hold
-11.00%
Downside
Reiterated
03/27/26
J.P. Morgan Keeps Their Hold Rating on Surgery Partners (SGRY)
UBS Analyst forecast on SGRY
A.J. Rice
UBS
UBS
$29→$21
Buy
33.50%
Upside
Reiterated
03/10/26
Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Benchmark Co. Analyst forecast on SGRY
Bill Sutherland
Benchmark Co.
Benchmark Co.
$24
Buy
52.57%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (NASDAQ: RLMD), Surgery Partners (NASDAQ: SGRY) and Apogee Therapeutics (NASDAQ: APGE)
KeyBanc Analyst forecast on SGRY
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Hold
―
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Surgery Partners (NASDAQ: SGRY), Axsome Therapeutics (NASDAQ: AXSM) and Pennant Group (NASDAQ: PNTG)
TD Cowen Analyst forecast on SGRY
Gary Taylor
TD Cowen
TD Cowen
$17→$19
Buy
20.79%
Upside
Assigned
08/11/26
TD Cowen Sticks to Their Buy Rating for Surgery Partners (SGRY)
RBC Capital Analyst forecast on SGRY
Ben Hendrix
RBC Capital
RBC Capital
$20→$19
Buy
20.79%
Upside
Reiterated
08/10/26
Analysts Are Bullish on Top Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Surgery Partners (SGRY)
Cantor Fitzgerald Analyst forecast on SGRY
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$18
Buy
14.43%
Upside
Reiterated
08/10/26
Surgery Partners' improved cash conversion not priced in, says Cantor FitzgeraldSurgery Partners' improved cash conversion not priced in, says Cantor Fitzgerald
Mizuho Securities Analyst forecast on SGRY
Ann Hynes
Mizuho Securities
Mizuho Securities
$19
Buy
20.79%
Upside
Reiterated
07/13/26
Mizuho Securities Sticks to Their Buy Rating for Surgery Partners (SGRY)
Bank of America Securities Analyst forecast on SGRY
Joanna Gajuk
Bank of America Securities
Bank of America Securities
$17.5
Buy
11.25%
Upside
Reiterated
05/14/26
Bank of America Securities Remains a Buy on Surgery Partners (SGRY)
Barclays Analyst forecast on SGRY
Andrew Mok CFA
Barclays
Barclays
$14
Hold
-11.00%
Downside
Assigned
05/12/26
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), Sarepta Therapeutics (NASDAQ: SRPT) and Surgery Partners (NASDAQ: SGRY)
Jefferies Analyst forecast on SGRY
Brian Tanquilut
Jefferies
Jefferies
$15→$17
Buy
8.07%
Upside
Reiterated
05/06/26
Raising PT to $17. With operations stabilizing, we believe we can now give SGRY credit for +HSD% LT EBITDA growth. Applying our coverage universe's avg valuation at 1.1x EBITDA growth rate to SGRY's earnings outlook translates to a 10x target multiple/our revised $17PT.
J.P. Morgan Analyst forecast on SGRY
Benjamin Rossi
J.P. Morgan
J.P. Morgan
$14
Hold
-11.00%
Downside
Reiterated
03/27/26
J.P. Morgan Keeps Their Hold Rating on Surgery Partners (SGRY)
UBS Analyst forecast on SGRY
A.J. Rice
UBS
UBS
$29→$21
Buy
33.50%
Upside
Reiterated
03/10/26
Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Surgery Partners

3 Months
Brian TanquilutJefferies
Success Rate
17/30 ratings generated profit
57%
Average Return
+7.20%
Copying Brian Tanquilut's trades and holding each position for 3 Months would result in 56.67% of your transactions generating a profit, with an average return of +7.20% per trade.
1 Year
Brian TanquilutJefferies
Success Rate
15/30 ratings generated profit
50%
Average Return
+10.77%
Copying Brian Tanquilut's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +10.77% per trade.
2 Years
Brian TanquilutJefferies
Success Rate
10/30 ratings generated profit
33%
Average Return
-2.36%
Copying Brian Tanquilut's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -2.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SGRY Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
3
3
0
0
1
Buy
7
12
6
6
4
Hold
2
4
2
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
19
8
8
6
In the current month, SGRY has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SGRY average Analyst price target in the past 3 months is 18.64.
Each month's total comprises the sum of three months' worth of ratings.

SGRY Financial Forecast

SGRY Earnings Forecast

Next quarter’s earnings estimate for SGRY is $0.12 with a range of $0.06 to $0.17. The previous quarter’s EPS was $0.10. SGRY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year SGRY has Performed in-line its overall industry.
Next quarter’s earnings estimate for SGRY is $0.12 with a range of $0.06 to $0.17. The previous quarter’s EPS was $0.10. SGRY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year SGRY has Performed in-line its overall industry.

SGRY Sales Forecast

Next quarter’s sales forecast for SGRY is $853.43M with a range of $838.08M to $861.00M. The previous quarter’s sales results were $848.90M. SGRY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year SGRY has Performed in-line its overall industry.
Next quarter’s sales forecast for SGRY is $853.43M with a range of $838.08M to $861.00M. The previous quarter’s sales results were $848.90M. SGRY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year SGRY has Performed in-line its overall industry.

SGRY Stock Forecast FAQ

What is SGRY’s average 12-month price target, according to analysts?
Based on analyst ratings, Surgery Partners Inc.’s 12-month average price target is 18.64.
    What is SGRY’s upside potential, based on the analysts’ average price target?
    Surgery Partners Inc. has 18.52% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SGRY a Buy, Sell or Hold?
          Surgery Partners Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Surgery Partners Inc.’s price target?
            The average price target for Surgery Partners Inc. is 18.64. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $24.00 ,the lowest forecast is $14.00. The average price target represents 18.52% Increase from the current price of $15.73.
              What do analysts say about Surgery Partners Inc.?
              Surgery Partners Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of SGRY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.